In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Beta Bionics Inc’s stock clocked out at $30.4, up 6.89% from its previous closing price of $28.44. In other words, the price has increased by $6.89 from its previous closing price. On the day, 0.69 million shares were traded. BBNX stock price reached its highest trading level at $30.9899 during the session, while it also had its lowest trading level at $28.36.
Ratios:
To gain a deeper understanding of BBNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 01, 2025, Goldman Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $26.Truist initiated its Buy rating on June 16, 2025, with a $26 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Lezack Adam sold 1,406 shares for $29.55 per share. The transaction valued at 41,543 led to the insider holds 8,435 shares of the business.
Palasis Maria sold 1,406 shares of BBNX for $41,552 on Dec 01 ’25. The Director now owns 8,435 shares after completing the transaction at $29.55 per share. On Oct 31 ’25, another insider, Lezack Adam, who serves as the Director of the company, sold 1,406 shares for $26.87 each. As a result, the insider received 37,780 and left with 9,841 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 1338348800 and an Enterprise Value of 1117348736. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.11 while its Price-to-Book (P/B) ratio in mrq is 4.54. Its current Enterprise Value per Revenue stands at 12.615 whereas that against EBITDA is -16.596.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $32.71, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 22.42%, while the 200-Day Moving Average is calculated to be 67.62%.
Shares Statistics:
It appears that BBNX traded 777.31K shares on average per day over the past three months and 461700 shares per day over the past ten days. A total of 43.99M shares are outstanding, with a floating share count of 33.41M. Insiders hold about 24.10% of the company’s shares, while institutions hold 94.81% stake in the company. Shares short for BBNX as of 1763078400 were 3572312 with a Short Ratio of 4.60, compared to 1760486400 on 4169413. Therefore, it implies a Short% of Shares Outstanding of 3572312 and a Short% of Float of 9.15.
Earnings Estimates
The dynamic stock of Beta Bionics Inc (BBNX) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.34 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.64 and -$2.06 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.66, with 6.0 analysts recommending between -$1.27 and -$2.0.
Revenue Estimates
In. The current quarter, 10 analysts expect revenue to total $28.9M. It ranges from a high estimate of $29.8M to a low estimate of $28M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 10 analysts are estimating revenue of $27.55M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $24.2M.
A total of 10 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $97.9M, while the lowest revenue estimate was $96.5M, resulting in an average revenue estimate of $97.13M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $132.25M in the next fiscal year. The high estimate is $143.98M and the low estimate is $121M.
